Reduction of proteinuria with angiotensin receptor blockers
Author:
Publisher
Springer Science and Business Media LLC
Subject
Cardiology and Cardiovascular Medicine,General Medicine
Link
http://www.nature.com/articles/ncpcardio0806.pdf
Reference43 articles.
1. Ruggenenti P et al. (1998). Urinary protein excretion rate is the best independent predictor of ESRF in non-diabetic proteinuric chronic nephropathies. “Gruppo Italiano di Studi Epidemiologici in Nefrologia” (GISEN). Kidney Int 53: 1209–1216
2. Brewster UC and Perazella MA (2004) The renin-angiotensin-aldosterone system and the kidney: effects on kidney disease. Am J Med 116: 263–272
3. European Society of Hypertension-European Society of Cardiology Guidelines Committee (2003) 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 21: 1011–1053
4. Whitworth JA (2003) 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens 21: 1983–1992
5. Zidek W et al. (2003) New recommendations of the German Hypertension League for the drug treatment of hypertension. Dtsch Med Wochenschr 128: 2468–2469
Cited by 40 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Losartan and metabolite EXP3179 activate endothelial function without lowering blood pressure in AT2 receptor KO mice;European Journal of Pharmacology;2024-08
2. Losartan ameliorates renal fibrosis by inhibiting tumor necrosis factor signal pathway;Nefrología (English Edition);2024-03
3. Losartan ameliorates renal fibrosis by inhibiting tumor necrosis factor signal pathway;Nefrología;2023-09
4. Losartan metabolite EXP3179 is a unique blood pressure-lowering AT1R antagonist with direct, rapid endothelium-dependent vasoactive properties;Vascular Pharmacology;2022-12
5. Studying Telmisartan Plasma Exposure, Kidney Distribution, Receptor Occupancy, and Response in Patients With Type 2 Diabetes Using [ 11 C ]Telmisartan;Clinical Pharmacology & Therapeutics;2022-09-30
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3